OTCMKTS:HKMPF Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free HKMPF Stock Alerts $24.50 0.00 (0.00%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$24.50▼$24.5050-Day Range$22.33▼$26.5052-Week Range$21.28▼$27.15VolumeN/AAverage Volume68 shsMarket Capitalization$5.40 billionP/E RatioN/ADividend Yield3.84%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest Get Hikma Pharmaceuticals alerts: Email Address Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More HKMPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HKMPF Stock News HeadlinesApril 29, 2024 | markets.businessinsider.comCollegium Pharma Partners With Hikma For Authorized Generics Of Nucynta In USMarch 20, 2024 | msn.comHikma Pharmaceuticals PLC goes ex dividend tomorrowMay 8, 2024 | Weiss Ratings (Ad)[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?March 18, 2024 | finance.yahoo.comOptimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past weekFebruary 27, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC (HKMPF)February 22, 2024 | msn.comDrugmaker Hikma expects profit to be slightly lower in 2024February 22, 2024 | markets.businessinsider.comHikma Pharma FY Profit IncreasesFebruary 1, 2024 | msn.comHikma Pharmaceuticals did not report suspicious opioid orders for 15 years, NC Attorney General Josh Stein saysMay 8, 2024 | Weiss Ratings (Ad)[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?February 1, 2024 | marketwatch.comHikma Pharmaceuticals Agrees in Principle to Pay up to $115M in US Opioid SettlementFebruary 1, 2024 | finance.yahoo.comAd firm Publicis, drugmaker Hikma settle US opioid cases for $500 millionFebruary 1, 2024 | finance.yahoo.comUPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 millionJanuary 29, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?October 5, 2023 | finance.yahoo.comThe one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past weekOctober 3, 2023 | finance.yahoo.comStocks Open Lower, Weighed Down by Rising Bond YieldsAugust 10, 2023 | finance.yahoo.comRakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North AfricaAugust 9, 2023 | marketwatch.comHikma Appoints Bill Larkins as President of Injectables BusinessJuly 26, 2023 | finance.yahoo.comHikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseasesMay 6, 2023 | msn.comSelling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 MonthsApril 12, 2023 | lse.co.ukHikma Pharmaceutical appoints Injectables lead Mishlawi as new CEOApril 12, 2023 | nasdaq.comHikma Pharma Appoints Riad Mishlawi As CEO, Effective Sept. 1April 12, 2023 | marketwatch.comHikma Pharmaceuticals Appoints Riad Mishlawi CEOApril 12, 2023 | msn.comHikma Pharma names Mishlawi as next CEOApril 4, 2023 | finance.yahoo.comThose who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 57%March 18, 2023 | marketwatch.comHikma Pharmaceuticals rises Thursday, still underperforms marketMarch 15, 2023 | marketwatch.comHikma Pharmaceuticals falls Monday, still outperforms marketMarch 9, 2023 | finance.yahoo.comHikma expands impact in Canada with launches of new sterile injectable medicinesSee More Headlines Receive HKMPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/3 Dividend3/20/2024Dividend Payable5/03/2024Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:HKMPF Previous SymbolOTC:HKMPF CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760Fax44-20-7399-2761Employees8,800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.47 Current Ratio1.57 Quick Ratio0.90 Sales & Book Value Annual Sales$2.88 billion Price / Sales1.88 Cash Flow$3.33 per share Price / Cash Flow7.36 Book Value$10.03 per share Price / Book2.44Miscellaneous Outstanding Shares220,230,000Free FloatN/AMarket Cap$5.40 billion OptionableNot Optionable Beta0.51 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.8MMr. Riad Ali Mishlawi (Age 60)CEO & Director Comp: $1.1MMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $2.3MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMore ExecutivesKey CompetitorsOrion OyjOTCMKTS:ORINYZealand Pharma A/SOTCMKTS:ZLDPFAspen PharmacareOTCMKTS:APNHYGN Store Nord A/SOTCMKTS:GNNDYSino BiopharmaceuticalOTCMKTS:SBMFFView All Competitors HKMPF Stock Analysis - Frequently Asked Questions Should I buy or sell Hikma Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HKMPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HKMPF, but not buy additional shares or sell existing shares. View HKMPF analyst ratings or view top-rated stocks. How have HKMPF shares performed in 2024? Hikma Pharmaceuticals' stock was trading at $22.7850 at the beginning of the year. Since then, HKMPF stock has increased by 7.5% and is now trading at $24.50. View the best growth stocks for 2024 here. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Wednesday, March 6th. Stockholders of record on Friday, March 22nd will be given a dividend of $0.47 per share on Friday, May 3rd. The ex-dividend date is Wednesday, March 20th. This is an increase from the stock's previous dividend of $0.25. Read our dividend analysis for HKMPF. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPF) pays an annual dividend of $0.94 per share and currently has a dividend yield of 3.84%. Read our dividend analysis for HKMPF. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HKMPF) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.